bionlp-st-ge-2016-spacy-parsed Home  

PMC:1064895 / 2643-2906 JSONTXT 23 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T3888 3-5 IN denotes of
T3889 6-12 NNS denotes joints
T3890 13-15 IN denotes in
T3891 16-18 NNP denotes RA
T3892 19-20 NNP denotes [
T3893 20-21 CD denotes 1
T3894 21-22 NNP denotes ]
T3895 22-23 . denotes .
T3896 24-27 DT denotes The
T3897 28-37 JJ denotes favorable
T3898 38-46 JJ denotes clinical
T3899 47-55 NNS denotes benefits
T3900 56-64 VBN denotes obtained
T3901 65-69 IN denotes with
T3902 70-80 NNS denotes inhibitors
T3903 81-83 IN denotes of
T3904 84-89 NN denotes tumor
T3905 90-98 NN denotes necrosis
T3906 99-105 NN denotes factor
T3907 106-107 -LRB- denotes (
T3908 107-110 NNP denotes TNF
T3909 110-111 -RRB- denotes )
T3910 111-112 : denotes -
T3911 112-113 VBN denotes α
T3912 113-114 -RRB- denotes )
T3913 115-118 CC denotes and
T3914 119-130 NN denotes interleukin
T3915 131-132 -LRB- denotes (
T3916 132-134 NNP denotes IL
T3917 134-135 -RRB- denotes )
T3918 135-137 CD denotes -1
T3919 138-145 VBP denotes suggest
T3920 146-150 IN denotes that
T3921 151-154 DT denotes the
T3922 155-163 NN denotes blockade
T3923 164-166 IN denotes of
T3924 167-170 JJ denotes key
T3925 171-183 JJ denotes inflammatory
T3926 184-193 NNS denotes cytokines
T3927 194-197 VBZ denotes has
T3928 198-202 VBN denotes been
T3929 203-206 DT denotes the
T3930 207-216 JJ denotes important
T3931 217-222 NN denotes issue
T3932 223-225 IN denotes in
T3933 226-229 DT denotes the
T3934 230-241 NN denotes development
T3935 242-244 IN denotes of
T3936 245-248 JJ denotes new
T3937 249-260 JJ denotes therapeutic
R1922 T3889 T3888 pobj joints,of
R1925 T3891 T3892 compound RA,[
R1929 T3892 T3890 pobj [,in
R1934 T3893 T3894 nummod 1,]
R1939 T3894 T3892 appos ],[
R1947 T3896 T3899 det The,benefits
R1951 T3897 T3899 amod favorable,benefits
R1955 T3898 T3899 amod clinical,benefits
R1958 T3899 T3911 nsubj benefits,α
R1962 T3900 T3899 acl obtained,benefits
R1966 T3901 T3900 prep with,obtained
R1969 T3902 T3901 pobj inhibitors,with
R1973 T3903 T3902 prep of,inhibitors
R1977 T3904 T3905 compound tumor,necrosis
R1983 T3905 T3906 compound necrosis,factor
R1984 T3906 T3903 pobj factor,of
R1985 T3907 T3908 punct (,TNF
R1988 T3908 T3906 appos TNF,factor
R1990 T3909 T3900 punct ),obtained
R1993 T3910 T3899 punct -,benefits
R1997 T3911 T3911 ROOT α,α
R2000 T3912 T3911 punct ),α
R2004 T3913 T3911 cc and,α
R2008 T3914 T3919 nsubj interleukin,suggest
R2012 T3915 T3916 punct (,IL
R2015 T3916 T3914 appos IL,interleukin
R2019 T3917 T3918 punct ),-1
R2023 T3918 T3919 nsubj -1,suggest
R2026 T3919 T3911 conj suggest,α
R2033 T3920 T3928 mark that,been
R2037 T3921 T3922 det the,blockade
R2041 T3922 T3928 nsubj blockade,been
R2045 T3923 T3922 prep of,blockade
R2048 T3924 T3926 amod key,cytokines
R2052 T3925 T3926 amod inflammatory,cytokines
R2056 T3926 T3923 pobj cytokines,of
R2060 T3927 T3928 aux has,been
R2064 T3928 T3919 ccomp been,suggest
R2068 T3929 T3931 det the,issue
R2071 T3930 T3931 amod important,issue
R2075 T3931 T3928 attr issue,been
R2079 T3932 T3931 prep in,issue
R2081 T3933 T3934 det the,development
R2084 T3934 T3932 pobj development,in
R2087 T3935 T3934 prep of,development